



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/437,458	11/10/1999	ANTHONY GIORDANO	50093/014001	8009

7590 08/23/2002

KRISTINA BIEKER-BRADY PHD
CLARK AND ELBING LLP
176 FEDERAL STREET
BOSTON, MA 02110

EXAMINER

LEFFERS JR, GERALD G

ART UNIT	PAPER NUMBER
1636	23

DATE MAILED: 08/23/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/437,458	GIORDANO ET AL.
Examiner	Art Unit	
Gerry Leffers	1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 04 June 2002.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 3 and 12-34 is/are pending in the application.
- 4a) Of the above claim(s) 12-27 and 29-31 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 3,28 and 32-34 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input checked="" type="checkbox"/> Other: <i>detail action/attach</i> .

DETAILED ACTION

Continued Prosecution Application

The request filed on 1/28/02 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/437,458 is acceptable and a CPA has been established. An action on the CPA follows.

Election/Restrictions

Applicant's election without traverse of Group 17 (claims 3, 28 and 32-34, drawn towards SEQ ID NO: 170 in Paper No. 22 is acknowledged. Claims 3 and 12-34 are pending in the instant application, with claims 12-27 and 29-31 withdrawn from consideration as drawn towards non-elected inventions.

Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:
Non-initialed and/or non-dated alterations have been made to the oath or declaration. See 37 CFR 1.52(c).

The information for Ashish Xavier has non-initialed alterations to the name.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Art Unit: 1636

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 3, 28 and 32-34 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific (i.e. specific to the claimed invention) and substantial (i.e. that does not require further experimentation to establish a specific utility) asserted utility or a well established utility.

The rejected claims are directed towards an isolated fusion nucleic acid comprising a first nucleic acid (SEQ ID NO: 17) operably linked to a heterologous second nucleic acid and wherein the mRNA form of the first nucleic acids has RNA binding protein (RBP) binding activity or regulates the functionality of the mRNA form of the fusion nucleic acid. Hybrid transcripts comprising SEQ ID NO: 17 appear to be novel in the art. Therefore, there can be no well established utility for the claimed invention.

Asserted utilities for the claimed chimeric nucleic acids include 1) screening for compounds that affect the RBP binding activity of a particular RNA/RBP binding pair interaction, and/or the mRNA functionality; 2) to identify novel RNA/RBP binding pair interactions; and 3) to modify the expression of a protein encoded by the heterologous nucleic acid portion of the chimeric nucleic acid (e.g. page 10, first paragraph of the instant specification).

SEQ ID NO: 17 is disclosed in the instant specification as being obtained from the human leptin gene (Accession No. NM_000230). The specification generally describes an experiment where a protein extract from cells known to express leptin (3T3-L1) was used to demonstrate binding by an unidentified protein or proteins (RBPs) to an undescribed RNA comprising SEQ ID NO: 17 by either filter binding assay or gel filtration. While poly r(G), heparin and

Art Unit: 1636

“unrelated” RNAs were used as non-specific inhibitors in the binding assays, the exact composition of the competing RNAs is not disclosed by the instant specification, making it unclear how specific the observed protein binding actually was for the RNA comprising SEQ ID NO: 17. Also, the actual binding/gel shift data is not provided by the instant specification, making it even harder to determine the specificity of the RBP/RNA interactions in this case. According to the information available at the NCBI web page for Accession No. NM_000230, the sequence represented by SEQ ID NO: 17 is present as a 3' untranslated region in the transcript encoding human leptin.

The asserted utilities are not specific in that the protein or proteins that apparently bound the RNA comprising SEQ ID NO: 17 are not identified in the instant specification. For example, using the claimed nucleic acid hybrid to identify compounds that affect a specific RNA/RBP binding pair cannot be considered to be a specific in the absence of an identified RBP specific to SEQ ID NO: 17. Moreover, the ability of the nucleic acid comprising SEQ ID NO: 17 to modify expression of a protein encoded by the fusion transcript in a specific manner (i.e. stabilize, destabilize, sequester, etc.) has not been demonstrated. Therefore, using the chimeric nucleic acid to modify the expression of a protein cannot be considered a specific utility. Finally, use of the claimed chimeric nucleic acid to identify novel RBP/RNA binding pairs cannot be considered specific because it is not known that the proteins that bound the RNA in the binding assay described in the specification do not also bind other RNAs (e.g. RNAs other than the unrelated RNAs used as non-specific inhibitors of binding).

The asserted utilities are not substantial in that for each of the asserted activities, it would require further experimentation in order to confirm a specific utility. For example, it would

Art Unit: 1636

require further experimentation to determine the nature and number of different proteins responsible for binding the RNA comprising SEQ ID NO: 17 in the binding assay described in the specification. The asserted utility of using the chimeric nucleic acid to identify its own cognate binding proteins, if any, merely constitutes further experimentation to identify a specific activity.

Claims 3, 28 and 32-34 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 3, 28, 32-34 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The rejected claims are directed towards an isolated fusion nucleic acid comprising a first nucleic acid (SEQ ID NO: 17) operably linked to a heterologous second nucleic acid and wherein the mRNA form of the first nucleic acids has RNA binding protein (RBP) binding

activity or regulates the functionality of the mRNA form of the fusion nucleic acid. Regulating functionality can comprise an alteration in pre-mRNA processing or in the stabilization, translational efficiency, localization, sequestration, editing or splicing functions. Thus, the rejected claims embrace a number of different possible effects of SEQ ID NO: 17 on a chimeric transcript comprising SEQ ID NO: 17.

SEQ ID NO: 17 is disclosed in the instant specification as being obtained from the human leptin gene (Accession No. NM_000230). The specification generally describes an experiment where a protein extract from cells known to express leptin (3T3-L1) was used to demonstrate binding by an unidentified protein or proteins (RBPs) to an undescribed RNA comprising SEQ ID NO: 17 by either filter binding assay or gel filtration. The context of SEQ ID NO: 17 in the total transcript was not described. While poly r(G), heparin and “unrelated” RNAs were used as non-specific inhibitors in the binding assays, the exact composition of the competing RNAs is not described by the instant specification, making it unclear how specific the observed protein binding actually was for the RNA comprising SEQ ID NO: 17. Also, the actual binding/gel shift data is not provided by the instant specification, making it even harder to determine the specificity of the RBP/RNA interactions in this case. There are no relevant working examples or data provided by the instant specification demonstrating the effect the presence of the sequence of SEQ ID NO: 17 on functionality of a transcript comprising SEQ ID NO: 17. No structural/functional basis is provided in the specification for one of skill in the art to envision what are the functional effects, if any, of SEQ ID NO: 17 on a transcript comprising SEQ ID NO: 17.

According to the information available at the NCBI web page for Accession No. NM_000230, the sequence represented by SEQ ID NO: 17 is present as a 3' untranslated region in the transcript encoding human leptin. The prior art does not appear to disclose any embodiment wherein the sequence represented by SEQ ID NO: 17 has been used to modulate the functionality of any RNA, including its own. Therefore, the prior art does not offset the deficiencies of the instant specification as to the actual functional effects of SEQ ID NO: 17 on any transcript comprising the sequence.

Given that the claimed invention comprises a critical element of regulating mRNA functionality that embraces several different processes (e.g. stabilization, translational efficiency, etc.) and given the lack of a structural/functional basis in the instant specification or prior art to envision the actual effect of SEQ ID NO: 17 on a transcript comprising SEQ ID NO: 17, one of skill in the art would not be able to reliably envision the claimed invention. Therefore, one of skill in the art would reasonably conclude that applicants were not in possession of the claimed invention.

Response to Arguments

In response to a similar rejection under 35 U.S.C. 112, first paragraph, for lack of written description, applicants have submitted a declaration under 37 C.F.R. 1.132 from Dr. Anthony Giordano. The declaration by Dr. Giordano clearly teaches that the art recognizes that 5' and 3' UTRs can retain their RBP binding or regulatory activity when linked to heterologous coding sequences. However, the arguments presented by Dr. Giordano are moot as they do not address the current grounds of rejection. In the previous round of rejections, the basis for the rejection was the extremely broad genus of hybrid RNAs encompassed by the claims and the

unpredictability as to whether the claimed UTR sequences would retain their functional activities in the context of a given hybrid transcript. In the current round of rejections, the basis for the rejection is a lack of description of the functional activity (i.e. stabilization, destabilization, translational efficiency, etc.) would be for those embodiments where the claimed UTR (i.e. comprising SEQ ID NO: 17) confers a means of regulating mRNA functionality for the hybrid comprising the claimed UTR. The declaration provided by Dr. Giordano does not address this point.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3 and 32-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 3 and 32-34 are vague and indefinite in that is drawn towards non-elected embodiments (i.e. to SEQ ID NOS other than SEQ ID NO: 17). It would be remedial to amend the claim language to limit the embodiments to SEQ ID NO: 17.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by

Art Unit: 1636

raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 33 recites the broad recitation "wherein the nucleic acid is DNA", and the claim also recites "cDNA" which is the narrower statement of the range/limitation. It would be remedial to amend the claims by creating two different dependent claims reciting the limitations of "DNA" or "cDNA".

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr. whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7939 for regular communications and (703) 305-7939 for After Final communications.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Gerald G Leffers Jr.
Examiner
Art Unit 1636

AA2
ggl
August 20, 2002

DAVID GUZO
PRIMARY EXAMINER


09/437458
Attack Paper #23
File Copy



Nucleotide

PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Books
Search Nucleotide for						Go	Clear	
			Limits	Preview/Index	History	Clipboard	Details	
Display		default	Save	Text	Add to Clipboard			

1: NM_000230. Homo sapiens
lept...[gi:4557714]

MapView, Related Sequences, OMIM, Protein, PubMed,
SNP, Taxonomy, UniSTS, LinkOut

LOCUS LEP 3426 bp mRNA linear PRI 29-JAN-2002
 DEFINITION Homo sapiens leptin (obesity homolog, mouse) (LEP), mRNA.
 ACCESSION NM_000230
 VERSION NM_000230.1 GI:4557714
 KEYWORDS .
 SOURCE Homo sapiens.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 3426)
 AUTHORS Friedman, J.M., Leibel, R.L., Siegel, D.S., Walsh, J. and Bahary, N.
 TITLE Molecular mapping of the mouse ob mutation
 JOURNAL Genomics 11 (4), 1054-1062 (1991)
 MEDLINE 92147101
 PUBMED 1686014
 REFERENCE 2 (bases 1 to 3426)
 AUTHORS Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. and Friedman, J.M.
 TITLE Positional cloning of the mouse obese gene and its human homologue
 JOURNAL Nature 372 (6505), 425-432 (1994)
 MEDLINE 95075453
 PUBMED 7984236
 REFERENCE 3 (bases 1 to 3426)
 AUTHORS Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y et al.
 TITLE Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue
 JOURNAL Diabetes 44 (7), 855-858 (1995)
 MEDLINE 95309556
 PUBMED 7789654
 REFERENCE 4 (bases 1 to 3426)
 AUTHORS Green, E.D., Maffei, M., Braden, V.V., Proenca, R., DeSilva, U., Zhang, Y., Chua, S.C. Jr., Leibel, R.L., Weissenbach, J. and Friedman, J.M.
 TITLE The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7
 JOURNAL Genome Res. 5 (1), 5-12 (1995)
 MEDLINE 96352898
 PUBMED 8717050
 REFERENCE 5 (bases 1 to 3426)
 AUTHORS Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki T, Satoh N, Shigemoto M, Yoshimasa Y, Nishi S et al.
 TITLE Structural organization and chromosomal assignment of the human obese gene
 JOURNAL J. Biol. Chem. 270 (46), 27728-27733 (1995)
 MEDLINE 96070903
 PUBMED 7499240
 REFERENCE 6 (bases 1 to 3426)
 AUTHORS Gong, D.W., Bi, S., Pratley, R.E. and Weintraub, B.D.
 TITLE Genomic structure and promoter analysis of the human obese gene

JOURNAL J. Biol. Chem. 271 (8), 3971-3974 (1996)
MEDLINE 96223958
PUBMED 8626726
REFERENCE 7 (bases 1 to 3426)
AUTHORS Niki T, Mori H, Tamori Y, Kishimoto-Hashimoto M, Ueno H, Araki S, Masugi J, Sawant N, Majithia HR, Rais N et al.
TITLE Human obese gene: molecular screening in Japanese and Asian Indian NIDDM patients associated with obesity
JOURNAL Diabetes 45 (5), 675-678 (1996)
MEDLINE 96198511
PUBMED 8621021
REFERENCE 8 (bases 1 to 3426)
AUTHORS Comuzzie, A.G., Hixson, J.E., Almasy, L., Mitchell, B.D., Mahaney, M.C., Dyer, T.D., Stern, M.P., MacCluer, J.W. and Blangero, J.
TITLE A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2
JOURNAL Nat. Genet. 15 (3), 273-276 (1997)
MEDLINE 97207647
PUBMED 9054940
REFERENCE 9 (bases 1 to 3426)
AUTHORS Clement, K., Vaisse, C., Lahliou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.M., Basdevant, A., Bougnères, P., Lebouc, Y., Froguel, P. and Guy-Grand, B.
TITLE A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
JOURNAL Nature 392 (6674), 398-401 (1998)
MEDLINE 98196670
PUBMED 9537324
REFERENCE 10 (bases 1 to 3426)
AUTHORS Friedman, J.M. and Halaas, J.L.
TITLE Leptin and the regulation of body weight in mammals
JOURNAL Nature 395 (6704), 763-770 (1998)
MEDLINE 99010835
PUBMED 9796811
COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from U43653.1.
Summary: This gene is similar to the mouse obesity gene (ob). The protein encoded by this gene is secreted by white adipocytes. In the mouse study, mutations in this gene are linked to severe and morbid obesity.
FEATURES Location/Qualifiers
source 1..3426
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="7"
/map="7q31.3"
gene 1..3426
/gene="LEP"
/note="OB; OBS"
/db_xref="LocusID:3952"
/db_xref="MIM:164160"
CDS 57..560
/gene="LEP"
/note="leptin (murine obesity homolog); obesity (murine homolog, leptin)"
/codon_start=1
/product="leptin precursor"
/protein_id="NP_000221.1"
/db_xref="GI:4557715"
/db_xref="LocusID:3952"
/db_xref="MIM:164160"
/translation="MHWGTLCGFLWLWVYLYVQAVPIQKVQDDTKTLIKTIVTRIND
ISHTQSVSSKQKVTLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLE
NLRDLLHVLAFLSKSCHLPWASGLETLDSLGGVLEASGYSTEVVVALSRLQGSLQDMLWQ
LDLSPGC"

sig peptide 57..119
/uGene="LEP"
misc feature 120..557
/gene="LEP"
/note="Leptin"
/db_xref="CDD:pfam02024"
mat peptide 120..557
/gene="LEP"
/product="leptin"
variation 384
/gene="LEP"
/allele="A"
/allele="G"
/db_xref="dbSNP:1800564"

BASE COUNT 887 a 799 c 920 g 820 t

ORIGIN

1 gtaggaatcg cagcgccaac ggttgcaagg cccaaagaagc catcctggga aggaaaaatgc
61 attggggAAC cctgtcgga ttcttgcggc tttggcccta tctttctat gtccaaagctg
121 tgcCcAtccA aaaagtcAA gatgacacca aaaccctcat caagacaatt gtcaccagga
181 tcaatgacat ttcacacacg cagtcaGtct cctccaaaca gaaagtcacc gtttggact
241 tcattcctgg gctccacccc atcctgaccc tatccaagat ggaccagaca ctggcagtct
301 accaacagat cctcaccagt atgccttcca gaaacgtat ccaaataatcc aacgacctgg
361 agaacctccg ggatcttctt cacgtctgg ccttctctaa gagctgccac ttgcctggg
421 ccagtggcct ggagacctt gacagcctgg ggggtgtcct ggaagcttca ggctactcca
481 cagaggtggt ggccttgAGC aggctgcagg ggtctctgca ggacatgctg tggcagctgg
541 acctcagccc tgggtgctga ggccttgaag gtcactcttc ctgcaaggac tacgttaagg
601 gaaggaactc tggcttccag gtatctccag gattgaagag cattgcattt acacccctta
661 tccaggactc tgtcaattt cctgactcct ctaagccact cttccaaagg cataagaccc
721 taagcctcct tttgcttcaa accaaagata tatacacagg atcctattt caccaggaag
781 ggggtccacc cagcaaagag tgggctgcat ctgggattcc caccaaaggc ttcaagccatc
841 aacaagagtt gtcttgcCc ctcttgcacc atctccccc cactgaatgc ctcaatgtga
901 ccaggggtaa tttcagagag ggcagagggg taggcagagc ctttggatga ccagaacaag
961 gttccctctg agaattccaa ggagttccat gaagaccaca tccacacacg caggaactcc
1021 cagcaacaca agctggaaAGC acatgtttat ttattctgca ttttattctg gatggatttg
1081 aagcaaAGCA ccagttctc caggctctt ggggtcagcc agggccaggg gtctccctgg
1141 atgcagttt ccaatccccat agatgggtct ggctgagctg aacccatttt gagtgaactcg
1201 aggggtgggt tcatctgAGC aagagctggc aaagggtggct ctccagttt tagtctcgta
1261 actggttca tttctactgt gactgatgtt acatcacagt gtttcaatg gtgtgccct
1321 gagtggatct ccaaggacca gtttattttt aaaagattt ttttgcattt gtttgcattt
1381 aggtgtctgc acccagggggt ggggaatgtt tggcagaaAGC ggagaaggat ctagaatgtg
1441 ttttctgaat aacatttgc tgggtgggtt ttttgcattt gtttgcattt ttttgcattt
1501 tctgcaattt cttaggatgt ttttgcattt aatagctttt tcagggggggt ttttgcattt
1561 gcccaggcac cccctggaga gaagtttctg gcccctggctg accccaaaga gcctggagaa
1621 gctgatgctt tgcttcaat ccatcccgaa taaaacgcAA agggctgaaa gcccattttt
1681 ggggcagtgg taagctctgg ctttctccgA ctgcttagggA gtggctttc ctatcatggA
1741 gtacgggtcc cacactgggt actgcgtatc tcagagcagg ggtccttgggt gtgaccctct
1801 gaatgggtcc aggggtgatc acactctggg ttttgcattt ggcagtgtt cttttgggg
1861 ctgcattgttcc aaatttgcattt ttttgcattt ttttgcattt ggcagtgtt cttttgggg
1921 aaaaatcttgg ggggggtttt actccagggtt ttttgcattt ttttgcattt ggcagtgtt
1981 agacctgaca agcactgtt ggcgagtgc aggactcccc aggccaggcc accaggatgc
2041 cttcccaact ggaggtcaca ttcaggaaAGC ttttgcattt ggcagtgtt cttttgggg
2101 cttgcattgttcc ttgggtttttt actccagggtt ttttgcattt ggcagtgtt cttttgggg
2161 tcaaaggcgtt taacttttgc ttttgcattt ttttgcattt ggcagtgtt cttttgggg
2221 aggctggaga agctcacccaa ataaacattt agattgaggc ttttgcattt ggcagtgtt
2281 ttcccagggtt tcaaaccgc ctttgcattt ttttgcattt ggcagtgtt cttttgggg
2341 gaacagccaa atgcattgtt ctttgcattt ttttgcattt ggcagtgtt cttttgggg
2401 ccgtgcccAGC gggcccacAGC ggaaccctgc ttgcattttt ttttgcattt ggcagtgtt
2461 gcatcttgc ttttgcattt ttttgcattt ttttgcattt ggcagtgtt cttttgggg
2521 taagaaaata cataaggacca taacagccaa ctttgcattt ttttgcattt ggcagtgtt
2581 tcctctgata cccagagcat tacgttgcattt ttttgcattt ggcagtgtt cttttgggg
2641 gagcgctttc tggaaaAGAGC gagtttgcattt ttttgcattt ggcagtgtt cttttgggg
2701 ttgcctgcAGC agagaAGC ttttgcattt ttttgcattt ggcagtgtt cttttgggg
2761 aagtgtgAGC agtgcattt ttttgcattt ttttgcattt ggcagtgtt cttttgggg
2821 atgcattgttggc gaccttgcAGC ggttttgcattt ttttgcattt ggcagtgtt cttttgggg
2881 ttcttagagaa gaggctgggtt ttttgcattt ttttgcattt ggcagtgtt cttttgggg

2941 gatcctcaca accacctaatt caggctgagg tgtcttaagc ctttgctca caaaacctgg
3001 cacaatggct aattcccaga gtgtgaaact tcctaagtat aaatggttgt ctgtttttgt
3061 aacttaaaaa aaaaaaaaaa agtttggccg ggtgcggtgg ctcacgcctg taatcccagc
3121 actttggag gccaagggtgg ggggatcaca aggtcaactag atggcgagca tcctggccaa
3181 catggtaaaa ccccgtctct actaaaaaca caaaagtttag ctgagcgtgg tggcgggcgc
3241 ctgttagtccc agccactcgg gaggctgaga caggagaatc gcttaaacct gggaggcgg
3301 gagtacagtg agccaagatc ggcactgc actccggcct gatgacagag cgagattccg
3361 tcttaaaaaa aaaaaaaaaa aaagtttgtt tttaaaaaaa tctaaataaa ataactttgc
3421 cccctg

//

Revised: July 5, 2002.

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jul 16 2002 16:59:14

Attach #23

L Number	Hits	Search Text	DB	Time stamp
1	857	giordano-\$in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 19:57
7	268	xavier-\$in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 19:57
13	3	giordano-\$in. and xavier-\$in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 19:58
19	2	6273893.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 19:58
25	1122	giordano-\$in. or xavier-\$in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 19:59
31	7	(giordano-\$in. or xavier-\$in.) and utr	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 20:00
37	1	(giordano-\$in. or xavier-\$in.) and leptin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 20:01
43	206	leptin with (gene or rna or message or transcript or cdna)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 20:02
49	10	(leptin with (gene or rna or message or transcript or cdna)) with (fusion or chimer\$4 or hybrid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/08/19 20:03

US-PAT-NO: 6258559

DOCUMENT-IDENTIFIER: US 6258559 B1

TITLE: Method for producing proteins in transformed Pichia

----- KWIC -----

In the following examples, *Pichia methanolica* strain PMAD16 was used as a host strain. This strain is derived from type strain CBS 6515 and is described by Raymond et al., *Yeast* 14:11 (1998), and by Raymond, "Recombinant Protein Expression in *Pichia methanolica*," in *Gene Expression Systems: Using Nature for the Art of Expression*, Fernandez and Hoeffler (eds.), pages 193-209 (Academic Press, Inc. 1999). The host strain carries both alcohol utilization genes AUG1 and AUG2 and is deleted for PEP4 and PRB1 proteases. For these studies, the *Pichia* contained an expression vector derived from pCZR1 34, which comprises an AUG1 promoter, AUG1 terminator, and ADE2 as a selectable marker (Raymond et al., *Yeast* 14:11 (1998)). A chimeric gene comprising the following elements was inserted between the AUG1 promoter and terminator: a *S. cerevisiae* a-factor prepro sequence, a Glu:Glu tag or a FLAG tag, and a human leptin gene. The human leptin gene has been described by Zhang et al., *Nature* 372:425 (1994). An illustrative method for constructing a plasmid that comprises a human leptin gene is described by Raymond et al., *BioTechniques* 26:134 (1999), and an exemplary human leptin amino acid sequence is provided by SEQ ID NO:7 (GenBank accession No. 4139908).

(FILE 'HOME' ENTERED AT 20:06:59 ON 19 AUG 2002)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 20:07:08 ON 19 AUG 2002

L1 13478 S (GIORDANO, ?)/IN,AU
L2 2724 S (XAVIER, ?)/IN,AU
L3 6 S L1 AND L2
L4 16196 S L1 OR L2
L5 16 S L4 AND LEPTIN
L6 0 S L4 AND (LEPTIN (S) UTR)
L7 3 S L4 AND (LEPTIN (S) (GENE OR RNA OR TRANSCRIPT OR mRNA))
L8 1 DUPLICATE REMOVE L7 (2 DUPLICATES REMOVED)
L9 13 S L5 NOT L7
L10 5 DUPLICATE REMOVE L9 (8 DUPLICATES REMOVED)
L11 50 S (FUSION OR CHIMER? OR HYBRID) (S) (LEPTIN (S) (GENE OR RNA
OR
L12 3 S L11 (S) REPORTER
L13 1 DUPLICATE REMOVE L12 (2 DUPLICATES REMOVED)
L14 25 DUPLICATE REMOVE L11 (25 DUPLICATES REMOVED)
L15 17531 S (GONG, ?)/IN,AU
L16 22 S L15 AND LEPTIN
L17 11 S L16 AND (LEPTIN (S) (GENE OR RNA OR TRANSCRIPT OR mRNA))
L18 3 DUPLICATE REMOVE L17 (8 DUPLICATES REMOVED)

From: Fredman, Jeffrey
 Sent: Wednesday, June 12, 2002 3:00 PM
 To: STIC-Biotech/ChemLib
 Cc: Leffers, Gerald
 Subject: FW: 09/437,458

PLEASE RUSH.

I Approve.

Jeff Fredman

-----Original Message-----

From: Leffers, Gerald
 Sent: Wednesday, June 12, 2002 2:56 PM
 To: Fredman, Jeffrey
 Subject: 09/437,458

11A09
 1636
 11E12

Hi Jeff, please approve a RUSH search/interference search for this application for SEQ ID NO: 17 (~239 nucleotides).
 Thanks, Gerry Leffers

Pending Nucleic Acid and/or Pending Amino Acid database searches now generate two sets of results. These databases were split into two parts to reduce the time needed to update the databases daily. The split freed up more machine time for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions, .rnpm and .rnpn

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions, .rapm and .rapn

The Pending database search results should not be left in the case because they contain data that is confidential.

Searcher: D. Schreiber
 Phone: 308-4292
 Location: CM 6A03
 Date Picked Up: 6/13
 Date Completed: 6/14
 Searcher Prep/Review: _____
 Clerical: _____
 Online time: 5

TYPE OF SEARCH:
 NA Sequences: 1
 AA Sequences: _____
 Structures: _____
 Bibliographic: _____
 Litigation: _____
 Full text: _____
 Patent Family: _____
 Other: _____

VENDOR/COST (where applic.)
 STN: _____
 DIALOG: _____
 Questel/Orbit: _____
 DRLink: _____
 Lexis/Nexis: _____
 Sequence Sys.: _____
 WWW/Internet: _____
 Other (specify): Computer

neurodegeneration -
Claim 1; Page 30: 33PP: English.

Sequences AH27132 - AH27151 represent human gene untranslated regions where the corresponding mRNA fragment has RNA binding protein (RBP) binding activity. RBPs mediate the processing of pre-mRNA, the transport of mRNA from the nucleus to the cytoplasm, mRNA stabilization, translational efficiency, and the sequestration of some mRNAs. Therefore, modification of post-transcriptional protein expression in eukaryotic cells may be carried out through the targeting specific interactions of proteins that bind to RBPs. The gene fragments of the invention are used to identify their optimized sub-fragments, compounds that affect RNA/RBP interaction or mRNA functionality; or RBPs that interact with the compounds. Compounds identified using the gene fragments are potentially useful for therapeutic regulation of gene expression, such as in cases of neurodegeneration; stroke; cardiovascular disease; hypertension; cancer; inflammation; metabolic disorders (obesity and diabetes) and bacterial or viral infection. The present sequence is one of gene fragments of the invention, isolated from the human leptin gene.

Sequence 239 BP; 54 A; 32 C; 68 G; 85 T; 0 other;

20-SEP-2001.
12-MAR-2001; 2001WO-IB00722.
13-MAR-2000; 2000US-0188796.
08-DEC-2000; 2000US-0254464.
(ENGE-) ENGENE INC.
Kieffer TJ, Cheung AT;
WPI; 2001-582445/65.
P-PSDB; AAEI0338.

Novel isolated or cultured mucosal cell producing nutrient-regulatable protein expressed by transgene comprising expression control element linked with nucleic acid encoding protein, is useful for treating diabetes -

Disclosure; Fig 17-18; 75pp; English.

Db 1338 agtggatctccaaaggaccaggatttaaaagattttttcactgttcactatgtta 1397
 CC associated with cancer, or for cosmetic reasons in humans, or for
 CC production of Kobe beef or Foie gras in domestic animals. OBP antibodies
 CC (Ab) can also be used in diagnostic immunoassays for the presence of OBP.
 CC The formation of Ab-OBP complexes enables *in vitro* evaluation of levels
 CC of OBP in a sample, especially to detect diseases associated with
 CC elevated or decreased levels, and to monitor treatment of these diseases.
 CC

Db 1398 99tgtctgcacccaaagggtggaaatgtttttggcagaaggatggaaatgtt 1457
 CC

Db 1458 ttctcgaatcacattttgtgggggttttggaaaggatggatcatttttatct 1516
 CC

RESULT 5
 ID AAT16372 standard; cDNA; 2793 BP.
 XX
 AC AAT16372;
 XX
 DT 11-SEP-1996 (first entry)
 AC Obesity protein coding sequence.
 AC Obesity; mouse; OBP; leptin; hormone; body weight regulation; diabetes;
 KW food intake; energy expenditure; high blood pressure; cholesterol; human;
 KW gene therapy; antibody; cancer; Kobe beef; Foie gras; immunoassay; ds.
 XX
 OS Mus musculus.
 XX
 Key CDS Location/Qualifiers
 FT 57..560
 FT /*tag= a
 FT /product= obesity protein
 FT 57..119
 FT /*tag= b
 FT 120..557
 FT /*tag= c
 GB2292382-A.
 XX
 PN 21-FEB-1996.
 PD XX
 XX
 PR 17-AUG-1995; 95GB-0016947.
 PR 07-JUN-1995; 95US-0483211.
 PR 17-AUG-1994; 94US-0292345.
 PR 30-NOV-1994; 94US-0347563.
 PR 10-MAY-1995; 95US-0438431.
 XX
 PA (UYRQ) UNIV ROCKEFELLER.
 Burley SK, Friedman JM, Gajiwala K, Halaas JL, Maffei M;
 Proenca R, Zhang Y;
 XX
 DR WPI; 1995-099009/11.
 DR P-PSDB; AAK92719.
 XX
 PT Obesity polypeptide(s) able to modulate body wt. - useful for e.g.
 PT reducing wt. in treatment of diabetes, high blood pressure and high
 PT cholesterol and for cosmetic reasons
 XX
 PS Claim 26; Page 167-169; 304PP; English.

XX
 CC This sequence represents the coding sequence for the mouse obesity
 CC polypeptide (OBP). OBP (also known as leptin) is a hormone involved in
 CC the regulation of body weight. The encoded sequence has effects on both
 CC food intake and energy expenditure. OBP and its analogues are useful for
 CC modifying body weight (optionally combined with known medicaments), for
 CC treating diabetes, high blood pressure or high cholesterol. This
 CC sequence (and sequences complementary to it) can be used in gene therapy
 CC for modifying body weight. The encoded protein can be used for reducing
 CC weight for health or cosmetic reasons in obese humans, or to produce
 CC leaner food animals. Antagonists of OBP (including antibodies) are
 CC useful for increasing body weight, e.g. for treating weight loss

RESULT 5
 ID AAT16372 standard; cDNA; 2793 BP.
 XX
 AC AAT16372;
 XX
 DT 11-SEP-1996 (first entry)
 AC Obesity protein coding sequence.
 AC Obesity; mouse; OBP; leptin; hormone; body weight regulation; diabetes;
 KW food intake; energy expenditure; high blood pressure; cholesterol; human;
 KW gene therapy; antibody; cancer; Kobe beef; Foie gras; immunoassay; ds.
 XX
 OS Mus musculus.
 XX
 Key CDS Location/Qualifiers
 FT 57..560
 FT /*tag= a
 FT /product= obesity protein
 FT 57..119
 FT /*tag= b
 FT 120..557
 FT /*tag= c
 GB2292382-A.
 XX
 PN 21-FEB-1996.
 PD XX
 XX
 PR 17-AUG-1995; 95GB-0016947.
 PR 07-JUN-1995; 95US-0483211.
 PR 17-AUG-1994; 94US-0292345.
 PR 30-NOV-1994; 94US-0347563.
 PR 10-MAY-1995; 95US-0438431.
 XX
 PA (UYRQ) UNIV ROCKEFELLER.
 Burley SK, Friedman JM, Gajiwala K, Halaas JL, Maffei M;
 Proenca R, Zhang Y;
 XX
 DR WPI; 1995-099009/11.
 DR P-PSDB; AAK92719.
 XX
 PT Obesity polypeptide(s) able to modulate body wt. - useful for e.g.
 PT reducing wt. in treatment of diabetes, high blood pressure and high
 PT cholesterol and for cosmetic reasons
 XX
 PS Claim 26; Page 167-169; 304PP; English.

XX
 CC This sequence represents the coding sequence for the mouse obesity
 CC polypeptide (OBP). OBP (also known as leptin) is a hormone involved in
 CC the regulation of body weight. The encoded sequence has effects on both
 CC food intake and energy expenditure. OBP and its analogues are useful for
 CC modifying body weight (optionally combined with known medicaments), for
 CC treating diabetes, high blood pressure or high cholesterol. This
 CC sequence (and sequences complementary to it) can be used in gene therapy
 CC for modifying body weight. The encoded protein can be used for reducing
 CC weight for health or cosmetic reasons in obese humans, or to produce
 CC leaner food animals. Antagonists of OBP (including antibodies) are
 CC useful for increasing body weight, e.g. for treating weight loss

RESULT 6
 ID AAC62565 standard; cDNA; 2793 BP.
 XX
 AC AAC62565;
 XX
 DT 01-FEB-2001 (first entry)
 AC Murine OB cDNA.
 XX
 KW Human; mouse; OB gene; obesity; adiposity; body weight; ss.
 OS Mus sp.
 XX
 PN US6124448-A.
 XX
 PD 26-SEP-2000.
 XX
 PR 07-JUN-1995; 95US-0488208.
 PR 17-AUG-1994; 94US-0293345.
 PR 30-NOV-1994; 94US-0347563.
 PR 10-MAY-1995; 95US-0438431.
 XX
 PA (UYRQ) UNIV ROCKEFELLER.
 PI Maffei M, Proenca R, Zhang Y, Friedman JM;
 XX
 DR WPI; 2000-601556/57.
 DR P-PSDB; AAB28447.
 XX
 PT Nucleic acid primers and probes useful for detecting mutations in
 PT mammalian OB gene associated with regulation of body weight and
 PT adiposity.
 XX
 PS Claim 1; Fig 1; 153pp; English.

XX
 CC The present sequence was used in an invention relating to the control of
 CC body weight of animals including humans. Nucleic acids of at
 CC least 10 nucleotides which are hybridisable to a non-coding region of an
 CC OB nucleic acid have been created. The OB gene plays a critical role in
 CC the regulation of body weight and adiposity. The nucleic acids may

be used as probes or as primers for PCR. They are useful for evaluating the presence of mutations in the human OB gene or for evaluating the level of expression of OB mRNA. Defects associated with OB gene expression result in obese phenotypes.

CC abnormal depression or elevation of body weight. The antibodies are used to treat weight loss associated with cancer, AIDS and anorexia nervosa. They are useful for the diagnosis of nutritional disorders such as obesity and diseases associated with obesity, such as hypertension, heart disease and type II diabetes. The kits are used to determine the presence or amount of α in the blood or plasma of an individual.

KW	antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW	acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW	neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW	gene; os.
XX	Homo sapiens.
OS	
XX	
PN	WO200200928-A2..
XX	
PD	03-JAN-2002.
XX	
PF	02-JUL-2001; 2001WO-EP07537.
XX	
PR	30-JUN-2000; 2000DE-10322529.
PR	01-SEP-2000; 2000DE-1043825.
XX	
PA	(EPICIG -) EPICENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WEI; 2002-130909-17.
XX	
PT	Nucleic acid comprising fragment of chemically modified gene, useful
PT	for diagnosis and treatment of diseases associated with abnormal
PT	cytosine methylation -
XX	
PS	Claim 1: SEQ ID NO 1168; 32pp + Sequence Listing; German.
XX	
CC	The present invention provides a number of human immune system associated
CC	genes which are modified by the methylation of cytosines. The sequences
CC	can be used in the diagnosis and treatment of immune system disorders,
CC	including eye diseases such as retinopathy, neovascular glaucoma and
CC	macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC	leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC	rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC	diseases. The present sequence is a gene of the invention.
XX	
Sequence	14861 BP; 3658 A; 228 C; 4018 G; 6955 T; 2 other;

AC	AAN70097;
XX	
DP	17-APR-1991 (first entry)
XX	
DE	Sequence of Ex promoter in E. coli expression plasmid
DE	PEP7-delta-P.
XX	
KW	Extracellular secretion; expression vector; ss.
XX	
FH	Key Location/qualifiers
FT	-35_Signal 44..49 /*tag= a
FT	-10_Signal 73..78 /*tag= b
FT	RBS 150..155 /*tag= c
FT	mRNA 85..169 /*tag= d
FT	CDS 170..311 /*tag= e
FT	
XX	
PN	EP216080-A.
XX	
PD	01-APR-1987.
XX	
PF	30-JUL-1986; 86EP-0110534.
XX	
PR	30-JUL-1985; 85JP-0168288.
XX	
PA	(RIKA) RIKAGAKU KENKYUSHO.
XX	
PI	Horikoshi K, Kudo T, Kato C, Kobayashi T;
XX	
DR	WRI; 1987-087874/13.
XX	
PT	New plasmid with DNA region inducing extracellular secretion of prod. - useful in transformed host microorganism for prodn. of enzymes, hormones, antiviral proteins etc.
PT	
XX	
PS	Disclosure; Fig 3; 39pp; English.
XX	
CC	Plasmid PEP7-delta-P (claimed) contains a DNA region which is capable of inducing extracellular secretion of useful, physiologically active substances in transformed host, (designated K gene) and a Promoter DNA gene which regulates expression of K gene (designated Ex promoter) and a genetic marker. Mechanism of the extracellular secretion is believed to be that K gene and Ex promoter make the outer membrane of E. coli more permeable.
CC	
SQ	Sequence 311 BP; 96 A; 41 C; 77 G; 97 T; 0 other;

Fri Jun 14 08:05:20 2002

us-09-437-458-17.rng

Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 111; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Matches 111; Conservative 0; Mismatches 74; Indels 6; Gaps 2;

RESULT 4

US-08-488-214A-1

Sequence 1, Application US/08488214A

Patent No. 6124439

GENERAL INFORMATION:

APPLICANT: MARGHERITA MAFFEI, JEFFREY HALAS, KEVIN GAUTIWALA, AND STEPHEN K. BURLE

TITLE OF INVENTION: OB POLYPEPTIDE ANTIBODIES AND METHOD OF MAKING

TITLE OF INVENTION: (AS AMENDED)

NUMBER OF SEQUENCES: 99

CORRESPONDENCE ADDRESS:

ADDRESSEE: Klauber & Jackson

STREET: 411 Hackensack Avenue

CITY: Hackensack

STATE: New Jersey

COUNTRY: USA

ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: FLOPPY disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08488,214A

FILED DATE: JUNE 7, 1995

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/347,563

FILED DATE: NO. 6124439ember 30, 1994

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/292,345

FILED DATE: August 17, 1994

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Jackson Esq., David A.

REGISTRATION NUMBER: 26,742

REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2D

TELECOMMUNICATION INFORMATION:

TELEPHONE: 201 487-8800

TELEFAX: 201 343-1684

TELEX: 133521

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 2193 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPLOGY: linear

MOLECULE TYPE: DNA (genomic)

DESCRIPTION: Murine ob cDNA

HYPOTHETICAL: NO

ANTI-SENSE: NO

ORIGINAL SOURCE:

ORGANISM: Murine

FEATURE: CDS

NAME/KEY: CDS

LOCATION: 57..560

RESULT 5

US-08-488-208A-1

Sequence 1, Application US/08488208A

Patent No. 6124448

GENERAL INFORMATION:

APPLICANT: THE ROCKEFELLER UNIVERSITY

TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEAR ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

NUMBER OF SEQUENCES: 98

CORRESPONDENCE ADDRESS:

ADDRESSEE: Klauber & Jackson

STREET: 411 Hackensack Avenue

CITY: Hackensack

STATE: New Jersey

COUNTRY: USA

ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: FLOPPY disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08488,208A

FILED DATE: 07-JUN-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/485, 943

FILED DATE: June 7, 1995

APPLICATION NUMBER: 08/438, 431

FILED DATE: May 10, 1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/347, 563

FILED DATE: NO. 6124448ember 30, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/292, 345

FILED DATE: August 17, 1994

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Jackson Esq., David A.

REGISTRATION NUMBER: 26,742

REFERENCE/DOCKET NUMBER: 600-1-087 CIP 2D

TELECOMMUNICATION INFORMATION:

TELEPHONE: 201 487-8800

TELEFAX: 201 343-1684

TELEX: 133521

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

LENGTH: 2193 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPLOGY: linear

MOLECULE TYPE: DNA (genomic)

DESCRIPTION: Murine ob cDNA

HYPOTHETICAL: NO

ANTI-SENSE: NO

ORIGINAL SOURCE:

ORGANISM: Murine

FEATURE: CDS

NAME/KEY: CDS

LOCATION: 57..560

INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:

Query Match 33.7%; Score 80.6; DB 3; Length 2793;

TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 DESCRIPTION: Murine ob cDNA

ANTI-SENSE: NO
 ORIGINAL SOURCE: Murine
 FEATURE: CDS
 LOCATION: 57..560

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1225 CTCGTTGTCATGAGATGAGATGTTAGAGGGGTCAGGCC-- 1281

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1282 -GGGAGCATAGGCTAGGTATATCAAAAGCAGATGAAATTGCAAGTATATGTA 1339

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1282 -GGGAGCATAGGCTAGGTATATCAAAAGCAGATGAAATTGCAAGTATATGTA 1339

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1340 TCTATGCACTGAGGTAGAGATGTTAGAGGGGTCAGGCC-- 1398

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1399 TCTCTGAATTACATATGTTGGAGGCCTTCGAAAGGGTGAGGCATT 1449

Query Match 33.7%; Score 80.6; DB 3; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1399 TCTCTGAATTACATATGTTGGAGGCCTTCGAAAGGGTGAGGCATT 1449

RESULT 6

US-08-483-211A-1

Sequence 1, Application US/08483211A

Patent No. 630983

GENERAL INFORMATION:

APPLICANT: THE ROCKEFELLER UNIVERSITY
 TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

NUMBER OF SEQUENCES: 98

CORRESPONDENCE ADDRESS:

ADDRESSEE: Klauber & Jackson

STREET: 411 Hackensack Avenue

CITY: Hackensack

STATE: New Jersey

COUNTRY: USA

ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/483-211A

FILED DATE: 07-JUN-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/485, 943

FILED DATE: June 7, 1995

APPLICATION NUMBER: 08/438, 431

FILED DATE: May 10, 1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/347, 563

FILED DATE: No. 630953emember 30, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/292, 345

FILED DATE: August 17, 1994

CLASSIFICATION: 514
 ATTORNEY/AGENT INFORMATION:
 NAME: Jackson Esq., David A.

REGISTRATION NUMBER: 26,742
 REFERENCE/DOCKET NUMBER: 600-1-087 CIP21
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 201 487-5800
 TELEX: 133521

INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 2793 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: Linear
 MOLECULE TYPE: DNA (genomic)
 DESCRIPTION: Murine ob cDNA
 HYPOTHETICAL: NO
 ANTI-SENSE: NO
 ORIGINAL SOURCE:
 ORGANISM: Murine
 FEATURE: CDS
 NAME/KEY: CDS
 LOCATION: 57..560

US-08-483-211A-1

Query Match 33.7%; Score 80.6; DB 4; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1225 CTCGTTGTCATGAGATGAGATGTTAGAGGGGTCAGGCC-- 1281

Query Match 33.7%; Score 80.6; DB 4; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1282 -GGGAGCATAGGCTAGGTATATCAAAAGCAGATGAAATTGCAAGTATATGTA 1339

Query Match 33.7%; Score 80.6; DB 4; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1340 TCTATGCACTGAGGTAGAGATGTTAGAGGGGTCAGGCC-- 1398

Query Match 33.7%; Score 80.6; DB 4; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1399 TCTCTGAATTACATATGTTGGAGGCCTTCGAAAGGGTGAGGCATT 1449

Query Match 33.7%; Score 80.6; DB 4; Length 2793;
 Best Local Similarity 65.4%; Pred. No. 4e-17; Matches 151; Conservative 0; Mismatches 74; Indels 6; Gaps 2; Db 1399 TCTCTGAATTACATATGTTGGAGGCCTTCGAAAGGGTGAGGCATT 1449

RESULT 7

US-08-488-223A-1

Sequence 1, Application US/08488223A

Patent No. 6350730

GENERAL INFORMATION:

APPLICANT: THE ROCKEFELLER UNIVERSITY
 TITLE OF INVENTION: MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES

NUMBER OF SEQUENCES: 98

CORRESPONDENCE ADDRESS:

ADDRESSEE: Klauber & Jackson

STREET: 411 Hackensack Avenue

CITY: Hackensack

STATE: New Jersey

COUNTRY: USA

ZIP: 07601

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/488-223A

FILED DATE: 07-Jun-1995

CLASSIFICATION: <Unknown>


```

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
IMMEDIATE SOURCE:
CLONE: Tyrosine Kinase
FEATURE:
NAME/KEY: CDS
LOCATION: 879..2364
US-08-447-408-1

```

```

Qy  83 tattttaaaagatttgttgtcaatgtcatatgttagtgtgtgcacccagggtgg 142
      Query Match 11.6%; Score 27.8; DB 1; Length 3098;
      Best Local Similarity 50.4%; Pred. No. 8.9;
      Matches 68; Conservative 0; Mismatches 67; Indels 0; Gaps 0

```

QY	143	gaatgttgccaggaggatctaatgttgttgtaaatccatgttg 302
Db	301	ATCTTTAGTATACAAATTAGGAGATATAAATGTTGTTGAGTGTACTAGTTA 242
QY	203	tggttcttggaa 217
Db	241	TGATAATAAGAAG 227

Search completed: June 13, 2002, 15:19:07
Job time: 8959 sec

Search completed:
Job time: 8959 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

Om nucleic - nucleic search, using sw model.

Run on: June 13, 2002, 12:49:48 ; Search time 1868.55 Seconds

(without alignments)
2676.644 Million cell updates/sec

Title: US-09-437-458-17
Perfect score: 239
Sequence: 1 ctggtttcattttactgtg.....gtggatcatttttatc 239

Scoring table: IDENTITY-NUC
Gappen 10.0 , Gapext 1.0

Maximum DB seq length: 0
Post-processing: Minimum Match 0%, Maximum Match 100%
Listing first 45 summaries

Database:

GenBmbl: *
1: gb_ba: *
2: gb_hhg: *
3: gb_in: *
4: gb_om: *
5: gb_ov: *
6: gb_ptt: *
7: gb_ph: *
8: gb_pl: *
9: qb_pr: *
10: qb_ri: *
11: qb_sts: *
12: qb_sy: *
13: qb_un: *
14: qb_v1: *
15: em_ba: *
16: em_fun: *
17: em_hum: *
18: em_in: *
19: em_mu: *
20: em_on: *
21: em_or: *
22: em_ov: *
23: em_pat: *
24: em_ph: *
25: em_pl: *
26: em_ro: *
27: em_sts: *
28: em_un: *
29: em_v1: *
30: em_htg_hum: *
31: em_htg_inv: *
32: em_hg_other: *
33: em_htgo.inv: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	Match Length	DB ID	Description
NO.	Score			

Result	Query	Match Length	DB ID	Description
NO.	Score			

ALIGNMENTS

RESULT	1	AR164465	AR164465	AR164465	Sequence 17 from patent US 6273893.	239 bp	DNA	linear	PAT 17-OCT-2001
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
UNCLASSIFIED									
REFERENCE	1 (bases 1 to 239)								
AUTHORS	McAllen,J. III, Overaker,D.W. and Cooper,K.L.								
TITLE	Absorbable rivet/pin applier for use in surgical procedures								
JOURNAL	Patent: US 6273893-A 17-14 AUG-2001;								
FEATURES	Location/Qualifiers								
SOURCE	1. -239 /organism="unknown"								
BASE COUNT	54 a 32 c 68 g 85 t								
ORIGIN									

Query	Match Length	DB ID	Description
Query match	100.0%	Score 239;	DB 6; Length 239;
Best Local Similarity	100.0%	Pred. No. 6.4e-62;	

AR164465 Sequence
AX003702 Sequence
AX331545 Sequence
U43653 Human obese
D63710 Human ob ge
G31731 SMSS2619 Er
AC018635 Homo sapi
AB041360 Felis cat
A310264 Ovis arie
AB02086 Canis fam
E59801 Canine obsi
AR17517 Sequence
AX088104 Sequence
U18812 Mus musculus
AC072048 Mus muscu
AF026976 Sus scrofa
AF052691 Sus scrofa
U66254 Sus scrofa
U50365 Bos taurus
AC096035 Rattus no
AL136123 Human DNA
AC097392 Rattus no
AC087806 Papio cyn
AC091093 Papio cyn
AC095090 Rattus no
AC094608 Rattus no
AX347260 Sequence
AC025485 Homo sapi
AC099366 Rattus no
AC031982 Homo sapi
AL590309 Homo sapi
AL589740 Human DNA
AX281268 Sequence
AX345063 Sequence
Continuation (4 of
AP000559 Oryza sat
AC099097 Rattus no
AC103200 Rattus no
AC009957 Homo sapi
AC101427 Mus muscu
AC069371 Homo sapi
AP002780 Homo sapi

Primer B: TGCTTAGAGGAGTCAGGGA
 PTS size: 106
 PCR Profile:
 Presoak: 0 degrees C for 0.00 minute(s)
 Denaturation: 92 degrees C for 0.17 minute(s)
 Annealing: 50 degrees C for 1.00 minute(s)
 Polymerization: 72 degrees C for 1.00 minute(s)
 PCR Cycles: 35
 Thermal Cycler: PerkinElmer 9600

Protocol:
 Template: 30-100 ng
 Primer: each 1 μ M
 DNTPs: each 200 μ M
 Taq Polymerase: 0.05 units/ μ l
 Total Vol: 10 μ l

Buffer:
 MgCl2: 1.5 mM
 KCl: 10 mM
 Tris HCl: 5 mM
 NH4Cl: 8.6

This SRS has been incorporated into the NHGRI chromosome 7 Physical map, but was developed by another investigator. See GenBank record: D63710 For additional information about the NHGRI chromosome 7 mapping project, see <http://www.ncbi.nlm.nih.gov/DIR/GBT/CHR7>. Also see Genomics 11:548-64 (1991) [MUR-92128337].

FEATURES
 source
 Location/Qualifiers
 1. .4522
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="7"
 /clone_id="Eric D. Green"
 gene
 1. .4522
 /gene="OBS"
 423. .528
 /gene="OBS"
 primer_bind
 /gene="OBS"
 primer_bind
 complement(509. .528)
 BASE COUNT
 ORIGIN
 1189 a 1032 c 1177 g 1124 t

Query Match 100.0%; Score 239; DB 11; Length 4522;
 Best Local Similarity 100.0%; Pred. No. 56-22; Mismatches 239; Conservative 0; Indels 0; Gaps 0;

1 ctggttccatcttactgtgactgtatggatccatcacatggttcaatgtgttgcctg 60
 Db 1092 CTGGTTCACTTCTACTGTGACTGTGATCCTACAGTGTTGCAATGGTTGCCCTG 1151
 Qy 61 atggatctccaaaggccatgttttaaaaggatgtttgtcaatgttgcataatqta 120
 Db 1152 AGGGATCTCCAGGACAGGTATTTAAAGATGTTGTTGTCAGTGTCATATGTA 1211
 Qy 121 gggtgtcgccacccagggtggaaatgttggcagaaggagaaggatcgatgt 180
 Db 1212 GGTGTCAGCACCCAGGGTGGGAATCTGGAGAGGGAGATCTGAAATGTTG 1271
 Qy 181 ttttcaataacacattgtgtgggttttggaaaggatcgatctttatct 239
 Db 1272 TTCTCTATACATCTTGTGCTTGTGAGGAGTCAGATCTTCTTAATCT 1330

RESULT 7
 AC018635 AC018635 163549 bp DNA linear PRI 15-NOV-2001
 LOCUS Homo sapiens chromosome 7 clone RP11-621I, complete sequence.
 DEFINITION AC018635
 ACCESSION AC018635.7
 VERSION GI:16930995

KEYWORDS
 SOURCE
 ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1e3549)
 AUTHORS Kaul, R.K., Olson, M.V., Zhou, Y., James, R.A., Raymond, C. and Haugen, E.D.
 TITLE Direct Submission
 JOURNAL Unpublished
 2 (bases 1 to 1e3549)
 AUTHORS Babb, K.L., Desmarais, C.L., Ramsey, S.A. and Hubley, R.M.
 TITLE Direct Submission
 JOURNAL Submitted (15-DEC-1999) Human Genome Center, University of Washington, Box 352145, Seattle, WA 98195, USA
 3 (bases 1 to 1e3549)
 AUTHORS Kaul, R.K., Olson, M.V., Zhou, Y., James, R.A., Raymond, C., Clendenning, J., Ivey, R.G. and Haugen, E.D.
 TITLE Direct Submission
 JOURNAL Submitted (31-MAR-2001) Genome Center, University of Washington, Box 352145, Seattle, WA 98195, USA
 4 (bases 1 to 1e3549)
 On Nov 15, 2001 this sequence version replaced gi:13491250.
 COMMENT -----
 REFERENCE
 AUTHORS Kaul, R.K., Olson, M.V., Zhou, Y., James, R.A., Raymond, C. and Haugen, E.D.
 TITLE Direct Submission
 JOURNAL Submitted (15-NOV-2001) Genome Center, University of Washington, Box 352145, Seattle, WA 98195, USA
 CENTER
 Center: University of Washington Genome Center
 Center Code: UWGC
 Web site: <http://www.genome.washington.edu>
 Contact: uwgc@genen.washington.edu

 PROJECT INFORMATION
 Center project name: chr-7
 Center clone name: RP11-62J1 (dts169)

 SUMMARY STATISTICS
 Assembly program: Phrap; version 0.990319
 Consensus quality: 163396 bases at least 040
 Consensus quality: 163533 bases at least 030
 Consensus quality: 163548 bases at least 020
 Insert size: 17712; 11.9% error; agarose-fp
 Insert size: 163559; sum-of-contigs
 Quality coverage: 9.0x in Q20 bases; agarose-fp
 Quality coverage: 9.7x in Q20 bases; sum-of-contigs

 OVERLAPPING SEQUENCES:
 5'; RP11-339C14 (UWGC:dts356) AC018662 20141-bp clone overlap
 3'; RP11-15514 (UWGC:dts356) AC018655 54910-bp clone overlap

 SEQUENCE QUALITY ASSESSMENT:
 This entry has been annotated with sequence quality estimates computed by the Phrap assembly program. All manually edited bases have been reduced to quality zero. Quality levels above 40 are expected to have less than 1 error in 10,000 bp. Base-by-base quality values are not generally visible from the GenBank flat file format but are available as part of this entry's ASN.1 file.

 This sequence was finished as follows unless otherwise noted: all regions were either double-stranded or sequenced with an alternate chemistry or covered by high quality data (i.e., Phred quality \geq 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one plasmid subclone or more than one M13 subclone; and the assembly was confirmed by restriction digest.

 SEQUENCE VALIDATION:
 This sequence has been validated by Multiple Complete Digest fingerprinting. Comparison of the experimentally derived digest fragments with sequence-predicted fragments is given below. The electronically-digested sequence consists of both insert and

vector, in order to accurately represent the entire circular BAC. Small fragments below a variable cutoff (approximately 400-800 bp) are not resolved in the fingerprint and hence do not appear in the table. There are no significant remaining discrepancies between the experimental and predicted values. Uniquely ordered fragments are separated by dashed lines.

Fri Jun 14 08:05:19 2002

us-09-437-458-17.rge

Page 10

Search completed: June 13, 2002, 15:50:57
Job time: 10869 sec

FEATURES		JOURNAL	
FEATURES	source	COMMENT	Submitted (23-JUL-1999) Genoscope - Centre National de Sequencage : BP 191 91006 ERY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr)
		Determination of this BAC-end sequence was carried out as part of a collaboration with the European Drosophila Genome Project (EDGP) - http://www.edgp.ebi.ac.uk/. This Drosophila melanogaster BAC library (Dros BAC) was made by Alain Billaud at CEPH (Centre d'Etude du Polymorphisme Humain) with funding provided by a MRC project grant. The DNA was prepared from embryos by Alain Bucheton and Geneviève Payan. It has been constructed in the vector pBeloBAC11.	- Web : www.genoscope.cns.fr
		Location/Qualifiers	Location/Qualifiers
		1. 1201	1. 1201
		/organism="Drosophila melanogaster"	/organism="Drosophila melanogaster"
		/plasmid="pBeloBAC11"	/plasmid="pBeloBAC11"
		/db_xref="taxon:7227"	/db_xref="taxon:7227"
		/clone_id="DrosBAC"	/clone_id="DrosBAC"
		/clone="BAC115019"	/clone="BAC115019"
		/note="end : T7"	/note="end : T7"
BASE COUNT	360 a 103 c 276 g 188 t 274 others	BASE COUNT	360 a 103 c 276 g 188 t 274 others
ORIGIN	183 a 106 c 100 g 152 t	ORIGIN	183 a 106 c 100 g 152 t
FEATURES		FEATURES	
FEATURES	source	COMMENT	Insert Length: 685 Std Error: 0.00
		Seq primer: TCAACAGGAACAGCTATGAC.	Plate: 010 row: E column: 03
		/clone="NP010E03IN"	Seg primer: TCAACAGGAACAGCTATGAC.
		/clone_1b="Insect herbivory"	Location/Qualifiers
		/tissue_type="local and systemic leaves"	1. 541
		/dev_stage="mature"	/dev_stage="mature"
		/note="Vector: Lambda Zap; Library was produced from fully expanded M. truncatula leaves of plants fed upon by Spodoptera exigua (peet armyworm) for 24 hours. Systemic (undamaged leaves from injured plants) and wounded leaves were harvested and pooled"	/note="Vector: Lambda Zap; Library was produced from fully expanded M. truncatula leaves of plants fed upon by Spodoptera exigua (peet armyworm) for 24 hours. Systemic (undamaged leaves from injured plants) and wounded leaves were harvested and pooled"
RESULT	7	RESULT	8
LOCUS	BE322138	LOCUS	BM121183
DEFINITION	NF010E03INF1020 Insect herbivory	DEFINITION	NIA Mouse Newborn Kidney cDNA Library (Long) Mus
REFERENCE	NP010E03IN 5', mRNA sequence.	REFERENCE	BM121183
AUTHORS	ESTRISON, L.	AUTHORS	BM121183.1
KEYWORDS	EST.	KEYWORDS	EST:17089209
VERSION	EST.	VERSION	EST
KEYWORDS	EST.	KEYWORDS	EST
SOURCE	house mouse.	SOURCE	house mouse.
ORGANISM	Mus musculus	ORGANISM	Mus musculus
COMMENT		COMMENT	
		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. (bases 1 to 621)	
		1. (bases 1 to 621)	
		Piao, Y., Kargul, G.J., Dudekula, D.B., Qian, Y., Pantano, S., Lim, M.K. and Ko, M.S.H.	
		Systematic Analyses of NIA Mouse Newborn Kidney cDNA Library	
		Unpublished (2001)	
		Contact: Dawood B. Dudekula	
		Laboratory of Genetics	
		National Institute on Aging/National Institutes of Health	
		333 Cassell Drive, Suite 4000, Baltimore, MD 21224-6820, USA	
		Email: cDNA@nigms.nih.gov	
		Plate: L0949 row: E column: 03	
		Seq primer: -21M3 Forward	
		High quality sequence stop: 621	
		POLYN="yes	
FEATURES		FEATURES	
FEATURES	source	COMMENT	COMMENT
		Location/Qualifiers	Location/Qualifiers
		1. 621	1. 621
		/organism="Mus musculus"	/organism="Mus musculus"
		/strain="C57BL/6J"	/strain="C57BL/6J"
		/db_xref="nla:SN:0949E03-3"	/db_xref="nla:SN:0949E03-3"
		/clone="L0949E03"	/clone="L0949E03"
		/tissue_type="Newborn Kidney"	/tissue_type="Newborn Kidney"
		/dev_stage="Newborn"	/dev_stage="Newborn"

FEATURES	source	Location/Qualifiers
		and how to order individual BAC clones, the entire library, or filters for hybridization from the BACPAC Resource Center can be found at http://bacpac.med.buffalo.edu/drosophila_bac.htm .
source		Location/Qualifiers
	1. .848	
		/organism="Drosophila melanogaster"
		/obj_xref="taxon:5227"
		/clone.lib="RPCI-98"
		/clone="BACR34B02"
		/note="end : TET3"
BASE COUNT	87	a 120 c 35 g 259 t 347 others
OPTCN		

RESULT 15
 CNS004YY/C
 LOCUS CNS004YY 859 bp DNA linear GSS 03-JUN-1999
 DEFINITION Drosophila melanogaster genome survey sequence TEP3 end of BAC #
 BACR1F03 of RPCI-98 library from Drosophila melanogaster (fruit
 fly), genomic survey sequence.
 ACCESSION AL055406
 VERSION AL055406.1 GI:4932207
 KEYWORDS GSS
 SOURCE fruit fly
 ORGANISM Drosophila melanogaster
 Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
 Pterygota; Neoptera; Endopterygota; Diptera; Brachycera;
 Muscomorpha; Ephydioidea; Drosophilidae; Drosophila.
 1 (bases 1 to 859)
 REFERENCE
 AUTHORS Genoscope
 TITLE JOURNAL
 Submitted (02-JUN-1999) Genoscope - Centre National de Sequençage :
 BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr
 MENT - Web : www.genoscope.cns.fr)
 Determination of this BAC-end sequence was carried out as part of a
 collaboration with the Berkeley Drosophila Genome Project (BDGP).
 The BDGP is constructing a physical map of the Drosophila
 melanogaster genome using these BACs. For further information
 please see <http://www.fruitfly.org>. The BDGP Drosophila
 melanogaster BAC library was prepared by Kazutoyo Osoegawa and
 Aaron Maiman in Pieter de Jong's laboratory in the Department of
 Cancer Genetics at the Roswell Park Cancer Institute in Buffalo,
 NY. The library is named RPCI-98 and was constructed by partial
 EcoRI digestion of Drosophila DNA provided by the BDGP from the
 isogenic strain y2; cn bw sp, the same strain used for the BDGP's
 P1 and EST libraries. A more detailed description of the library,
 and how to order individual BAC clones, the entire library, or
 filters for hybridization from the BACPAC Resource Center can be
 found at <http://bacpac.med.buffalo.edu/drosophila.bac.htm>.
 FEATURES
 source Location/Qualifiers
 1. 859
 /organism="Drosophila melanogaster"
 /db_xref="taxon:7227"
 /clone_id="RPCI-98"
 /clone="BACR1F03"
 /note="end : TEP3"
 BASE COUNT 302 a 32 c 15 g 124 t 386 others
 ORIGIN

Query Match 14.6%; Score 34.8; DB 12; Length 859;
 Best Local Similarity 13.9%; Pred. No. 24; Mismatches 64; Indels 0; Gaps 0;
 Matches 25; Conservative 91; Mismatches 64; Indels 0; Gaps 0;

```

<Y> 46 aatgggtgtgcctttagtgatctccaaaggccaggatattttaaaagattttgtttgt 105
     ::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|:
Db 816 RRTDRPRTRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR 757
Qy 106 caagtgtcatatgttagtgtgtgcacccagggtggaaatgtttggcagaaggaga 165
     ::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|:
Db 756 WRRRRRTTTRDRRRRTTDRDRTDRRRTDRRRTDRRRTDRRRTDRRRTDRR 697
Qy 166 ggatctagaatgtttcttaataacattgtgtgtgggtctttggagggatgaga 225
     ::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|:
Db 696 DRDWDRDRRRRGTRTRRRDARRRRRRDTTRGDRRTTDRRTARTTRARRRRRR 637

```

search completed: June 13, 2002, 15:17:37
 Job time: 8874 sec